FDA Approves New Combination Therapy for Thyroid Cancer


Tafinlar, Mekinist receive the go-ahead

Last week, the United States Food & Drug Administration approved dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) as a combination therapy for anaplastic thyroid cancer (ATC).

“This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer,” said Richard Pazdur, MD, acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

This same combination has been previously approved for treatment of BRAF-positive metastatic melanoma and non-small cell lung cancer.

“This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients,” said Pazdur.

ATC is a rather low-occurring form of thyroid cancer, accounting for only 1–2 of all cases (about 54,000 cases annually). The FDA reported encouraging data from trails with metastatic melanoma and non-small cell lung cancer.

Investigator in one recent trail reported out of 23 evaluable patients, 57 percent experienced a partial response and 4 percent experienced a complete response; in 9 (64 percent) of the 14 patients with responses, there were no significant tumor growths for 6 months or longer.

SOURCE: Medscape


188 words

About Author

Rob Senior
Rob Senior

Rob Senior has more than 15 years of experience covering, writing and editing industry news and content specific to the healthcare community and more than 10 years working for ADVANCE Healthcare Network. Rob Senior can be reached directly at rsenior@advanceweb.com.

Leave A Reply

Log in or register to comment on this article.